• Evaluation of efficacy of SVV-001 intratumoral injection combined with anti-PD-1 and anti- CTLA4 checkpoint blockade in an immunocompetent syngeneic pancreatic cancer murine model. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.